Fewer than a tenth of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to this class of drugs.
Based on projections, more than two billion could be obese by 2030 without intervention.
"The new guidelines acknowledges that obesity is a lifelong illness that can be managed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant hurdles to widespread access to the jabs that can help people shift considerable body mass, says the agency.
Skinny Jab Scarcity
Even under the current most favorable case, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation encourages governments and firms to widen access, via measures like licensing agreements.
A patent on semaglutide – the main component of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Jabs Function
These medications replicate a biological compound to reduce digestion speed, curb appetite and increase the sense of being full so individuals consume fewer calories.
Patients commonly begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research points to patients may regain a significant portion within a year of halting the drug, because their normal hunger come back.
Being above a healthy weight raises your likelihood for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight impacts people in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the health agency.
